Navigation Links
Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
Date:1/28/2013

CLEVELAND, Jan. 28, 2013 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease announced today that Paul Resnick , M.D., M.B.A., has joined the company as Vice President of Business Development.  Dr. Resnick brings more than 25 years of healthcare and business development experience to the role.  In this position, Dr. Resnick's efforts will be to drive business development efforts while supporting the company's broader corporate strategic vision.

(Logo: http://photos.prnewswire.com/prnh/20120820/DC59281LOGO )

Juventas' technology platform is based on developing factors that activate or enhance natural stem-cell based repair pathways.  The company is currently enrolling Phase II clinical trials in heart failure (HF) and critical limb ischemia (CLI) for lead product JVS-100.  JVS-100 encodes Stromal cell-Derived Factor 1 (SDF-1), which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death, and restoration of blood flow.  

Dr. Resnick's professional experience includes product and business development from early-stage private companies to top five pharmaceutical companies.  Most recently, Dr. Resnick led business development for Intellikine, culminating in its acquisition last year by Takeda Pharmaceuticals for $190 million upfront and up to $120 million in potential clinical milestones. He also played a key role in the Rinat Neurosciences acquisition by Pfizer in 2007 for $500 million in cash. 

"We are delighted to welcome Paul to Juventas' senior management team," commented Rahul Aras, President and Chief Executive Officer.  "Given the development stage and clinical potential for JVS-100, we believe having someone with Paul's experience focused on strategic opportunities will allow us to best recognize the long-term value of this platform."

"I'm thrilled to join the Juventas team," remarked Dr. Resnick.  "Juventas is pursuing a unique therapeutic strategy in the exciting field of regenerative medicine.  Through activation of a patient's own stem-cell repair processes, JVS-100 delivers regenerative benefits without the cost and complexities typically associated with cell-based therapeutics.  I look forward to applying my industry perspective and leveraging my contacts to help Juventas transition toward commercialization."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include Triathlon Medical Ventures, New Science Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Glengary, The Global Cardiovascular Innovation Center, Tri-State Growth Fund, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.


'/>"/>
SOURCE Juventas Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Juventas Therapeutics Raises $22.2 Million Series B Financing
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Shield Therapeutics Selects OpenClinica Enterprise
4. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
5. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
6. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
7. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
10. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
11. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially ... cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, ...
(Date:10/5/2017)... LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... innovators, engineers, and scientists from around the world, is giving back to cancer research ... sold in October. , Now through October 31, shoppers can use promo code ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):